EP 0746315 A4 19990107 - USE OF, AND METHOD OF TREATMENT USING, CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION
Title (en)
USE OF, AND METHOD OF TREATMENT USING, CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION
Title (de)
VERWENDUNG VON, UND BEHANDLUNGSVERFAHREN UNTER VERWENDUNG VON CARBAZOLYL-(4)-OXYPROPANOLAMINVERBINDUNGEN ZUR HEMMUNG DER PROLIFERATION VON ZELLEN DER GLATTEN MUSKULATUR
Title (fr)
EMPLOI DE COMPOSES CARBAZOLYLE-(4)-OXYPROPANOLAMINE POUR INHIBER LA PROLIFERATION CELLULAIRE DES MUSCLES LISSES ET METHODE DE TRAITEMENT ASSOCIEE
Publication
Application
Priority
- US 9308019 W 19930827
- US 9302062 W 19930305
- US 2689293 A 19930305
Abstract (en)
[origin: WO9420096A1] A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of formula (I):wherein R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent -CH2-0-; X is a valency bond, -CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl,indanyl and tetrahydronaphthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a -CONH2- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, for inhibition of proliferation of smooth muscle cells. The new use of, and method of treatment using, the present antiproliferative compounds prevent restenosis following percutaneous transluminal coronary angioplasty (PTCA) and prevent development of atherosclerosis.
IPC 1-7
IPC 8 full level
A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); C07D 209/88 (2006.01)
CPC (source: EP)
A61K 31/40 (2013.01); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 9/12 (2017.12)
Citation (search report)
- [DX] US 4503067 A 19850305 - WIEDEMANN FRITZ [DE], et al
- [X] MCTAVISH D ET AL: "CARVEDILOL A REVIEW OF ITS PHAMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, ANDTHERAPEUTIC EFFICACY", DRUGS, vol. 45, no. 2, 1 February 1993 (1993-02-01), pages 232 - 258, XP000578564
- [X] RUFFOLO R R ET AL: "CARVEDILOL: A NOVEL CARDIOVASCULAR DRUG WITH MULTIPLE ACTIONS", CARDIOVASCULAR DRUG REVIEWS, vol. 10, no. 2, 1 January 1992 (1992-01-01), pages 127 - 157, XP000578562
- See references of WO 9420097A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9420096 A1 19940915; AU 5092393 A 19940926; AU 679462 B2 19970703; EP 0746315 A1 19961211; EP 0746315 A4 19990107; JP H08508013 A 19960827; NO 307865 B1 20000613; NO 953480 D0 19950904; NO 953480 L 19951103; RU 2147433 C1 20000420; UA 41915 C2 20011015; WO 9420097 A1 19940915
DOCDB simple family (application)
US 9302062 W 19930305; AU 5092393 A 19930827; EP 93920350 A 19930827; JP 51993794 A 19930827; NO 953480 A 19950904; RU 95121695 A 19930827; UA 95083997 A 19930827; US 9308019 W 19930827